CSIMarket
 
Propanc Biopharma Inc   (PPCH)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 591
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Propanc Biopharma Inc
Propanc Biopharma Inc is a clinical-stage biopharmaceutical company that develops and commercializes treatment options for patients suffering from pancreatic cancer and various gastrointestinal cancers. The company focuses on developing proprietary formulations of proenzymes, which are inactive forms of enzymes, to activate enzymes that can target and destroy cancer cells. These proenzymes aim to improve the efficacy and safety of existing cancer treatments and have the potential to become a major advancement in cancer therapy. Propanc Biopharma is committed to conducting preclinical and clinical trials to develop its lead product, PRP, with the goal of gaining regulatory approval and bringing it to market.


   Company Address: 302 Camberwell 3124
   Company Phone Number: 9882-0780   Stock Exchange / Ticker: PPCH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        8.84% 
NRIX   -2.33%    
RYTM   -3.04%    
SUPN        3.11% 
YMAB        1.46% 
ZYME        5.78% 
• View Complete Report
   



Propanc Biopharma Inc

Propanc Biopharma Inc Reports Operating Deficit in Q3 2024 2.

Propanc Biopharma Inc is a company in the Major Pharmaceutical Preparations industry that has recently released its third quarter performance report for 2024. Despite not specifying any revenue for the reporting period of January to March 31, 2024, the company has reported an operating deficit of $-0.420867 million. This article aims to analyze the financial performance of Propanc Biopharma Inc in comparison to its previous performance in the third quarter of 2023, with a focus on the diminishing returns.
In the third quarter of 2023, Propanc Biopharma Inc had reported an operating deficit of $-0.386209 million. Although the company has not disclosed its revenue figures for the current reporting period, it is essential to consider the context of the previous year's performance to gauge the company's progress.
One promising aspect for Propanc Biopharma Inc is the receding of diminishing returns, which has decreased from $-0.810 million in the third quarter of 2023 to $-0.527 million in the same period of 2024. This trend indicates a positive trajectory for the company and suggests that it may emerge as a bellwether in the pharmaceutical industry.

Propanc Biopharma Inc

Propanc Biopharma Inc Shocks Investors with Operating Shortfall in Q2 of 2024

Investors were caught off guard by unexpected modifications at PPCH during the recent earnings season, with the company reporting an operating shortfall of $-0.438064 million for the October to December 31, 2023 period. This figure represents a significant increase from the previous year's operating shortfall.
Despite the disappointing financial results, the company's management has made key decisions to improve day-to-day operations, surpassing previous performance in this area. PPCH is focusing on its progress cycle, which is expected to drive future growth and profitability.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com